---
id: antimicrobials_ceftolozane-tazobactam_031
category: antimicrobials
tags: [antimicrobials, ceftolozane-tazobactam, C-T, pseudomonas, XDR, advanced-antibiotics]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Ceftolozane-Tazobactam (C-T)

**Q:** What is ceftolozane-tazobactam's niche, what is its spectrum, and when should it be used?

**A:**

**Mechanism:**
- **Ceftolozane:** Novel cephalosporin with enhanced anti-Pseudomonal activity
- **Tazobactam:** β-lactamase inhibitor

**Primary Niche:**
**BEST anti-Pseudomonas aeruginosa beta-lactam available**

**Spectrum - What it COVERS:**
- **MDR/XDR/PDR Pseudomonas aeruginosa**
  - 84.2% of all P. aeruginosa susceptible
  - 70% of MDR, 58% of XDR, 100% of PDR strains in some studies
  - Lowest resistance percentage among β-lactams for P. aeruginosa
- **ESBL-producing** Enterobacterales
- **AmpC-producing** organisms
- **Gram-positive cocci** (moderate activity)

**Spectrum - What it DOES NOT cover:**
- ❌ **CRE** (no KPC, MBL coverage)
- ❌ **Acinetobacter baumannii**
- ❌ **Anaerobes** (poor coverage, need metronidazole for cIAI)
- ❌ **MRSA**

**FDA-Approved Indications:**
1. **Complicated intra-abdominal infections (cIAI)** - with metronidazole
2. **Complicated urinary tract infections (cUTI)**, including pyelonephritis
3. **Hospital-acquired pneumonia (HAP)/Ventilator-associated pneumonia (VAP)**

**Dosing:**
- Standard: 1.5 g (ceftolozane 1 g + tazobactam 0.5 g) IV q8h
- HAP/VAP: 3 g (ceftolozane 2 g + tazobactam 1 g) IV q8h

**Mnemonic: "Ceftolozane = Pseudomonas KILLER"**
- **Drug of choice for XDR Pseudomonas**
- Think "**C-T for Pseudomonas**"

**Clinical Pearls:**
- Reserve for **MDR/XDR Pseudomonas** infections
- Resistance can develop during therapy (monitor susceptibilities)
- NOT for CRE (use CAZ-AVI or M-V instead)

| **Agent** | **Best For** | **NOT For** |
|-----------|--------------|-------------|
| **C-T** | MDR Pseudomonas | CRE, anaerobes |
| **CAZ-AVI** | KPC CRE, MDR Pseudomonas | MBL CRE |
| **M-V** | KPC CRE | MBL, Pseudomonas |

**Media:** None

**Sources:** [CID 2016 - Second-generation BL/BLI], [PMC 2021 - Systematic review respiratory infections], [Frontiers 2024 - XDR Pseudomonas Portugal], [Nature 2021 - Continuous infusion PK], [Frontiers 2020 - Cystic fibrosis]
